Cagrilintide is a long-acting amylin analog, engineered to extend amylin’s natural satiety signal from minutes to a full week between doses. At a molecular weight of approximately 4437.9 g/mol, it is a larger, modified peptide distinct from the GLP-1 class, acting through amylin receptors rather than GLP-1 receptors.
Research has examined standalone cagrilintide in a 706-adult phase 2 trial (weight reductions of approximately 6.0% to 10.8% across doses over 26 weeks, versus 3.0% on placebo), separately from a smaller phase 1b trial pairing it with semaglutide. Etched carries cagrilintide as a standalone compound, matching the population and dosing of the standalone trial.
Each Etched Research vial contains 10mg of lyophilized powder.
Specifications:
– Molecular Formula: C196H301N47O67
– Molecular Weight: ~4437.9 g/mol
– CAS: 1415456-99-3
– PubChem CID: 171397054
– InChIKey: LDERDVMBIYGIOI-IZVMHKDJSA-N
– Form: Lyophilized powder
– Storage: -20°C (lyophilized); 4°C once reconstituted, use within 30 days
FOR IN VITRO RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, INGESTION, OR ANY IN VIVO USE.
- What it is: A lab-made, long-acting amylin analog. Amylin is a natural hormone the body releases with insulin after a meal.
- Researchers have studied it for: body weight in adults with overweight or obesity, standalone and in combination trials. Etched carries cagrilintide on its own.
- Evidence level: Real human phase 1 and phase 2 trial data, plus animal mechanism work. Still mid-stage and investigational.
- The short version: A once-weekly amylin analog with real clinical trial data. Everything here is what happened in study models, not what it does for any person.

